October 8, 2011

Randomized trial of immunosuppressive regimens in renal transplantation

.   .   

Most randomized controlled trials of immunosuppressive regimens have follow-up of only one to three years, which may not be relevant in an era where average graft survival is a decade or more. This paper reports long-term results of a randomized controlled trial comparing tacrolimus/sirolimus, tacrolimus/mycophenolate mofetil and cyclosporine/sirolimus. All patients received induction with an interlukin-2 receptor antibody and maintenance steroids. With a median of eight years of follow-up, acute rejection rates were lowest and renal function best in the tacrolimus/MMF group. This study supports the tacrolimus/MMF combination as the immunosuppressive regimen of choice in renal transplantation.

Related Articles:

Renal Transplantation

Comments are closed.